Phase two multicentre study of arsenic trioxide in patients with myelodysplastic syndromes.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors CTI BioPharma
- 02 Oct 2020 Status changed from completed to discontinued.
- 25 Sep 2005 New trial record.